Morgan Stanley Downgrades ResMed (RMD) to Equalweight
RMD Hot Sheet
Rating Summary:4 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Morgan Stanley downgrades ResMed (NYSE: RMD) from Overweight to Equalweight.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
You May Also Be Interested In
- Omron Launches Sleep Monitor With ResMed Technology
- UBS Maintains a 'Neutral' on Ralcorp Holdings (RAH); Trimming Numbers After Q2 Miss
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
Create E-mail Alert Related Categories
DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
